Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Coland Holdings Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Coland Holdings Ltd (4144-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

25 Sep 2016 Thomson Reuters Stock Report 11 $25.00

Coland Pharmaceutical (4144 TT); Beneficiary of China’s Healthcare Reform

We believe Coland will become the major beneficiary of China’s healthcare reform given the support of a contract research org...

08 Sep 2016 MasterLink Securities Corporation 6 $58.00

康聯-KY(4144):中國醫藥改革趨勢的受惠者

元富分析,康聯有CRO公司的支援,且產品多為利基型/高附加價值之學名藥,在中國醫藥改革的趨勢下,康聯將成為主要受惠者,目前康聯評價偏低,具備投資價值,因此維持買進評等,目標價55元(11X2017EPS)。

05 Sep 2016 MasterLink Securities Corporation 5 $35.00

Wright Investors Service Comprehensive Report for Coland Holdings Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

05 Sep 2016 Wright Reports 64 $75.00

Thomson Reuters Stock Report - Coland Holdings Ltd (4144-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 11 $25.00

Coland Pharmaceutical (4144 TT); Beneficiary of China’s Healthcare Reform

M&A and non-operating business used to fuel Coland’s growth. After the drug procurement bidding process, Coland’s core busine...

08 Dec 2015 MasterLink Securities Corporation 6 $58.00

Coland Pharmaceutical (4144 TT): China Commenced Centralized Drug Procurement Bidding

Our sales forecast for 2015 is NT$2.5bn, +15% YoY, with estimated EPS of NT$5.41, and NT$3.49 excluding gain on disposal. We ...

15 Jan 2015 MasterLink Securities Corporation 7 $69.00

F-康聯 (4144):中國藥品集中招標已陸續展開

元富預估2015年營收25億元,YOY+15%,EPS 5.41元,扣除處分利益EPS 為3.49元;2016年新產品在各省陸續出貨,預估營收32億元,YOY +25%,EPS 6.81元,扣除處分利益EPS 為4.89元,YOY +41%。我們分析...

13 Jan 2015 MasterLink Securities Corporation 6 $46.00

Coland Pharmaceutical (4144 TT): Drug Bidding Schedule in China Remains Uncertain

We forecast Coland’s FY14 sales of NT$2.1bn with EPS of NT$5.29, and number will be NT$2.92 after leaving out gains from disp...

08 Oct 2014 MasterLink Securities Corporation 6 $58.00